|
"hsieh hp"的相关文件
显示项目 46-95 / 265 (共6页)
1 2 3 4 5 6 > >>
每页显示[10|25|50]项目
| 國家衛生研究院 |
2019-09-28 |
Design of drug-like hepsin inhibitors against prostate cancer and kidney stones
|
Blay, V;Li, MC;Ho, SP;Stoller, ML;Hsieh, HP;Houston, DR |
| 國家衛生研究院 |
2019-09-27 |
Discovery of a furanopyrimidine-based epidermal growth factor receptor inhibitor (DBPR112) as a clinical candidate for the treatment of non-small cell lung cancer
|
Lin, SY;Chang Hsu, Y;Peng, YH;Ke, YY;Lin, WH;Sun, HY;Shiao, HY;Kuo, FM;Chen, PY;Lien, TW;Chen, CH;Chu, CY;Wang, SY;Yeh, KC;Chen, CP;Hsu, TA;Wu, SY;Yeh, TK;Chen, CT;Hsieh, HP |
| 國家衛生研究院 |
2019-09 |
Design of a potent anticancer lead inspired by natural products from traditional Indian medicine
|
Arya, H;Yadav, CS;Lin, SY;Syed, SB;Charles, MRC;Kannadasan, S;Hsieh, HP;Singh, SS;Gajurel, PR;Coumar, MS |
| 國家衛生研究院 |
2019-07-21 |
Lysosomal cysteine protease cathepsin S is involved in cancer cell motility by regulating store-operated Ca(2+) entry
|
Lin, HH;Chen, SJ;Shen, MR;Huang, YT;Hsieh, HP;Lin, SY;Lin, CC;Chang, WW;Chang, JY |
| 國家衛生研究院 |
2019-07 |
Dual Kit/Aur inhibitors as chemosensitizing agents for the treatment of melanoma: Design, synthesis, docking studies and functional investigation
|
Quattrini, L;Coviello, V;Sartini, S;Di Desidero, T;Orlandi, P;Ke, YY;Liu, KL;Hsieh, HP;Bocci, G;La Motta, C |
| 國家衛生研究院 |
2019-05-29 |
Insights for the design of protein lysine methyltransferase G9a inhibitors
|
Charles, MRC;Dhayalan, A;Hsieh, HP;Coumar, MS |
| 國家衛生研究院 |
2018-11 |
Biomimetic Syntheses of (±)‐Isopalhinine A, (±)‐Palhinine A, and (±)‐Palhinine D
|
Chen, CM;Shiao, HY;Uang, BJ;Hsieh, HP |
| 國家衛生研究院 |
2018-07-26 |
Delineating the active site architecture of G9a lysine methyltransferase through substrate and inhibitor binding mode analysis: A molecular dynamics study
|
M, RCC;Hsieh, HP;Coumar, MS |
| 國家衛生研究院 |
2018-07 |
Clinical candidate DBPR112: A novel epidermal growth factor receptor inhibitor as a promising treatment for non-small cell lung cancer
|
Hsieh, HP;Chang, JY;Kuo, CC;Hsu, J |
| 國家衛生研究院 |
2018-07 |
Blockage of EGFR signaling repurposes tumor metabolism through suppression of glycolysis and Kreb cycle in head and neck cancer
|
Kuo, CC;Chang, JY;Hsieh, HP;Kung, HJ;Chang, HH;Huang, CH;Kuo, CC;Ke, YY |
| 國家衛生研究院 |
2018-05-10 |
Design and synthesis of BPR1K653 derivatives targeting the back pocket of Aurora kinases for selective isoform inhibition
|
Ke, YY;Chang, CP;Lin, WH;Tsai, CH;Chiu, IC;Wang, WP;Wang, PC;Chen, PY;Lin, WH;Chang, CF;Kuo, PC;Song, JS;Shih, C;Hsieh, HP;Chi, YH |
| 國家衛生研究院 |
2018-01 |
Discovery and development of DBPR112 as a clinical candidate: A novel EGFR inhibitor for non-small cell lung cancer
|
Hsieh, HP;Hsu, JTA;Yeh, TK;Chen, CT |
| 國家衛生研究院 |
2017-08-11 |
Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer
|
Syed, SB;Arya, H;Fu, IH;Yeh, TK;Periyasamy, L;Hsieh, HP;Coumar, MS |
| 國家衛生研究院 |
2017-07 |
Drug repurposing for chronic myeloid leukemia: In silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors
|
Singh, VK;Chang, HH;Kuo, CC;Shiao, HY;Hsieh, HP;Coumar, MS |
| 國家衛生研究院 |
2017-04 |
Toward the total syntheses of natural products containing trans-decalin skeleton from masked o-benzoquinone
|
Li, MC;Shiao, HY;Hsieh, HP |
| 國家衛生研究院 |
2017-04 |
Discovery of BPR1K871-a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation
|
Hsieh, HP;Wang, WC;Shiao, HY;Ke, YY;Lin, WH;Hsu, JTA;Chen, CT;Yeh, TK |
| 國家衛生研究院 |
2017-04 |
One-pot tandem oxidative dearomatization/ 4+3 cycloaddition: Masked o-benzoquinone with diaza-oxyallyl cation
|
Lee, KH;Hsieh, HP |
| 國家衛生研究院 |
2017-01-13 |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2016-12 |
Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation
|
Chang Hsu, Y;Selvaraj Coumar, M;Wang, WC;Shiao, HY;Ke, YY;Lin, WH;Kuo, CC;Chang, CW;Kuo, FM;Chen, PY;Wang, SY;Li, AS;Chen, CH;Kuo, PC;Chen, CP;Wu, MH;Huang, CL;Yen, KJ;Chang, YI;Hsu, JT;Chen, CT;Yeh, TK;Song, JS;Shih, C;Hsieh, HP |
| 國家衛生研究院 |
2016-11-29 |
Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design
|
Chang, CF;Lin, WH;Ke, YY;Lin, YS;Wang, WC;Chen, CH;Kuo, PC;Hsu, JTA;Uang, BJ;Hsieh, HP |
| 國家衛生研究院 |
2016-11-23 |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2016-07 |
Therapeutic polymeric nanoparticles and the methods of making and using thereof: A patent evaluation of WO2015036792
|
Sarvagalla, S;Hsieh, HP;Coumar, MS |
| 國家衛生研究院 |
2016-06-07 |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2016-03 |
Disruption of protein-protein interactions: Hot spot detection, structure-based virtual screening and in vitro testing for the anti-cancer drug target survivin
|
Sarvagalla, S;Cheung, CHA;Tsai, JY;Hsieh, HP;Coumar, MS |
| 國家衛生研究院 |
2015-08-20 |
Fused bicyclic pyrimidine compounds as Aurora kinase inhibitors
|
Coumar, MS;Chao, YS;Hsu, TA;Wu, SY;Hsieh, HP |
| 國家衛生研究院 |
2015-08 |
BPR2P001S0, a Coumarin derivative, induced cell cycle arrest in A549 through inhibiting PDPK1 activity
|
Lin, PH;Jao, TM;Hung, YL;Hsieh, HP;Yang, YC;Chang, SY |
| 國家衛生研究院 |
2015-08 |
Optimization of quinazoline-based kinase inhibitors: Identification of a dual FLT3/AURKA kinase inhibitor for the treatment of acute myeloid leukemia
|
Hsieh, HP;Hsu, YC;Ke, YY;Shiao, HY;Chang, CW;Lin, WH;Hsu, TA;Yeh, TK;Chen, CT |
| 國家衛生研究院 |
2015-08 |
Optimization of furanopyrimidine-based kinase inhibitors: Identification of a BTK kinase inhibitor for the treatment of B cell lymphoma
|
Wang, WC;Hsu, YC;Shiao, HY;Hung, HC;Kuo, CC;Lee, JC;Hsu, TA;Hsieh, HP |
| 國家衛生研究院 |
2015-08 |
Discovery of 2,4-diaminopyrimidines bearing a unique pharmacophore as anaplastic lymphoma kinase inhibitors
|
Shiao, HY;Wang, WC;Hsu, YC;Ke, YY;Hsu, TA;Hsieh, HP |
| 國家衛生研究院 |
2015-07-31 |
作為極光激酶抑制劑的稠合雙環嘧啶化合物
|
Hsieh, HP;Coumar, MS;Wu, SY;Hsu, TA;Chao, YS |
| 國家衛生研究院 |
2015-07-22 |
作为酪胺酸激酶抑制剂的稠合双环及多环嘧啶化合物
|
Hsieh, HP;Coumar, MS;Hsu, TA;Lin, WH;Chen, YR;Chao, YS |
| 國家衛生研究院 |
2015-06-29 |
Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification
|
Ke, YY;Singh, VK;Coumar, MS;Hsu, YC;Wang, WC;Song, JS;Chen, CH;Lin, WH;Wu, SH;Hsu, JT;Shih, C;Hsieh, HP |
| 國家衛生研究院 |
2015-04-14 |
Fused multicyclic compounds as protein kinase inhibitors
|
Hsieh, HP;Coumar, MS;Chao, YS |
| 國家衛生研究院 |
2015-02 |
Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors
|
Wu, CH;Wang, CJ;Chang, CP;Cheng, YC;Song, JS;Jan, JJ;Chou, MC;Ke, YY;Ma, J;Wong, YC;Hsieh, TC;Tien, YC;Gullen, EA;Lo, CF;Cheng, CY;Liu, YW;Sadani, AA;Tsai, CH;Hsieh, HP;Tsou, LK;Shia, KS |
| 國家衛生研究院 |
2015-01 |
Identification of ligand efficient, fragment-like hits from an HTS library: Structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity
|
Sarvagalla, S;Singh, VK;Ke, YY;Shiao, HY;Lin, WH;Hsieh, HP;Hsu, JTA;Coumar, MS |
| 國家衛生研究院 |
2014-12 |
BPR-3P0128 inhibits RNA-dependent RNA polymerase elongation and VPg uridylylation activities of Enterovirus 71
|
Balaji, VA;Chen, GW;Hsieh, PT;Horng, JT;Hsu, JTA;Hsieh, HP;Chen, TC;Weng, KF;Shih, SR |
| 國家衛生研究院 |
2014-11 |
Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent
|
Hsieh, HP;Kuo, CC;Chiu, JJ;Hsu, TA;Yeh, TK;Chen, CT |
| 國家衛生研究院 |
2014-10-29 |
作為極光激酶抑制劑的稠合雙環嘧啶化合物
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2014-10-21 |
化合物於製造治療病毒感染的藥物之用途
|
Hsieh, HP;Hsu, TA;Yeh, JY;Horng, JT;Shih, SR;Chang, SY;Chao, YS |
| 國家衛生研究院 |
2014-10 |
Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer
|
Lee, CC;Shiao, HY;Wang, WC;Hsieh, HP |
| 國家衛生研究院 |
2014-10 |
Optimization of 5,6-fused pyrimidine-based kinase inhibitors by computer-aided drug design for the treatment of AML
|
Hsu, YC;Shiao, HY;Ke, YY;Hsu, JTA;Lin, WH;Chen, CH;Hsieh, HP |
| 國家衛生研究院 |
2014-10 |
Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma
|
Shiao, HY;Hsu, TA;Lin, WH;Yang, TT;Hsieh, HF;Chen, CT;Yeh, TK;Hsieh, HP |
| 國家衛生研究院 |
2014-08 |
CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors
|
Chen, YP;Lin, HJ;Chen, JS;Tsai, MY;Hsieh, HP;Chang, JY;Chen, NF;Chang, KC;Huang, WT;Su, WC;Yang, ST;Chang, WC;Hung, LY;Chen, TY |
| 國家衛生研究院 |
2014-08 |
Ligand efficiency based approach for efficient virtual screening of compound libraries
|
Ke, YY;Coumar, MS;Shiao, HY;Wang, WC;Chen, CW;Song, JS;Chen, CH;Lin, WH;Wu, SH;Hsu, JT;Chang, CM;Hsieh, HP |
| 國家衛生研究院 |
2014-07 |
Anaplastic lymphoma kinase (ALK) inhibitors: A review of design and discovery
|
Wang, WC;Shiao, HY;Lee, CC;Fung, KS;Hsieh, HP |
| 國家衛生研究院 |
2014-05 |
Facile identification of dual FLT3-Aurora A inhibitors: A computer-guided drug design approach
|
ChangHsu, Y;Ke, YY;Shiao, HY;Lee, CC;Lin, WH;Chen, CH;Yen, KJ;Hsu, JTA;Chang, C;Hsieh, HP |
| 國家衛生研究院 |
2014-05 |
Cover Picture: Facile identification of dual FLT3–aurora a inhibitors: A computer-guided drug design approach (ChemMedChem 5/2014)
|
Chang Hsu, Y;Ke, YY;Shiao, HY;Lee, CC;Lin, WH;Chen, CH;Yen, KJ;Hsu, JTA;Chang, C;Hsieh, HP |
| 國家衛生研究院 |
2014-04-29 |
Quinoline compounds and their use for treating viral infection
|
Hsieh, HP;Hsu, TA;Yeh, JY;Chao, YS |
| 國家衛生研究院 |
2014-03-20 |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
|
Hsieh, HP;Coumar, MS;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2014-03 |
DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study
|
Shiao, HY;Hsu, TAJ;Chen, CT;Yeh, TK;Hsieh, HP |
显示项目 46-95 / 265 (共6页)
1 2 3 4 5 6 > >>
每页显示[10|25|50]项目
|
